DYN250117P50000
- 18.78
- 0.000.00%
Dyne Therapeutics Newsroom
PepGen Stock Craters 35% on FDA Clinical Hold
Baird Initiates Dyne Therapeutics(DYN.US) With Buy Rating, Announces Target Price $46
Dyne Therapeutics Initiated With an Outperform at Baird
Insider Sale: Chief Scientific Officer of $DYN (DYN) Sells 2,334 Shares
Dyne Therapeutics(DYN.US) Director Sells US$3.99 Million in Common Stock
Dyne Therapeutics(DYN.US) Director Sells US$4.08 Million in Common Stock
Dyne Therapeutics(DYN.US) Director Sells US$3.27 Million in Common Stock
Piper Sandler Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $53
Dyne Therapeutics Initiated at Outperform by RBC Capital
Dyne Therapeutics Analyst Ratings
RBC Capital Initiates Dyne Therapeutics(DYN.US) With Buy Rating, Announces Target Price $45
Form 144 | Dyne Therapeutics(DYN.US) Insider Proposes to Sell 49.25 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 14, $Dyne Therapeutics(DYN.US)$ Insider ForDyne B.V. intends to sell 1.5 million shares of its common stock on Nov 14, with a total market value of approximately $49.25
Dyne Therapeutics Reveals Q3 Results and Trial Updates
Dyne Therapeutics Is Maintained at Buy by Chardan Capital
Oppenheimer Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $55
Oppenheimer Sticks to Their Buy Rating for Dyne Therapeutics (DYN)
Express News | Dyne Therapeutics Inc : Raymond James Cuts Target Price to $49 From $56
H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $55
Dyne Therapeutics Receives Buy Rating Following IND Clearance and Promising Trial Updates
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $52